- Home
- XXII vs OGEN Comparison
XXII vs OGEN Comparison
Compare XXII & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- OGEN
- Stock Information
- Founded
- XXII 1998
- OGEN 1996
- Country
- XXII United States
- OGEN United States
- Employees
- XXII N/A
- OGEN N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- OGEN Health Care
- Exchange
- XXII Nasdaq
- OGEN Nasdaq
- Market Cap
- XXII 6.2M
- OGEN 5.4M
- IPO Year
- XXII N/A
- OGEN N/A
- Fundamental
- Price
- XXII $1.67
- OGEN $1.30
- Analyst Decision
- XXII
- OGEN
- Analyst Count
- XXII 0
- OGEN 0
- Target Price
- XXII N/A
- OGEN N/A
- AVG Volume (30 Days)
- XXII 341.7K
- OGEN 213.2K
- Earning Date
- XXII 11-04-2025
- OGEN 11-12-2025
- Dividend Yield
- XXII N/A
- OGEN N/A
- EPS Growth
- XXII N/A
- OGEN N/A
- EPS
- XXII N/A
- OGEN N/A
- Revenue
- XXII $21,362,000.00
- OGEN N/A
- Revenue This Year
- XXII N/A
- OGEN N/A
- Revenue Next Year
- XXII $126.57
- OGEN N/A
- P/E Ratio
- XXII N/A
- OGEN N/A
- Revenue Growth
- XXII N/A
- OGEN N/A
- 52 Week Low
- XXII $1.43
- OGEN $1.01
- 52 Week High
- XXII $394.02
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- XXII 52.22
- OGEN 48.72
- Support Level
- XXII $1.48
- OGEN $1.29
- Resistance Level
- XXII $1.62
- OGEN $1.34
- Average True Range (ATR)
- XXII 0.09
- OGEN 0.07
- MACD
- XXII 0.03
- OGEN -0.01
- Stochastic Oscillator
- XXII 65.57
- OGEN 22.50
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.